Show simple item record

dc.contributor.authorMalin, J.J.
dc.contributor.authorde Leeuw, E.en_US
dc.date.accessioned2019-10-22T14:48:38Z
dc.date.available2019-10-22T14:48:38Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85073373971&doi=10.2147%2fIDR.S215070&partnerID=40&md5=ffbee1972e527305a919b991e49b2222
dc.identifier.urihttp://hdl.handle.net/10713/11196
dc.description.abstractResistance against commonly used antibiotics has emerged in all bacterial pathogens. In fact, there is no antibiotic currently in clinical use against which resistance has not been reported. In particular, rapidly increasing urbanization in developing nations are sites of major concern. Additionally, the widespread practice by physicians to prescribe antibiotics in cases of viral infections puts selective pressure on antibiotics that still remain effective and it will only be a matter of time before resistance develops on a large scale. The biosynthesis pathway of the bacterial cell wall is well studied and a validated target for the development of antibacterial agents. Cell wall biosynthesis involves two major processes; 1) the biosynthesis of cell wall teichoic acids and 2) the biosynthesis of peptidoglycan. Key molecules in these pathways, including enzymes and precursor molecules are attractive targets for the development of novel antibacterial agents. In this review, we will focus on the major class of natural antibacterial compounds that target the peptidoglycan precursor molecule Lipid II; namely the glycopeptides, including the novel generation of lipoglycopeptides. We will discuss their mechanism-of-action and clinical applications. Further, we will briefly discuss additional peptides that target Lipid II such as the lantibiotic nisin and defensins. We will highlight recent developments and future perspectives. Copyright 2019 Malin and de Leeuw.en_US
dc.description.sponsorshipThis work was supported by Center for Biomolecular Therapeutics (PR155EDL1; UMB), a UM Ventures Seed Grant and Center for Maryland Advanced Ventures Grant to EdL.en_US
dc.description.urihttps://doi.org/10.2147/IDR.S215070en_US
dc.language.isoen_USen_US
dc.publisherDove Medical Press Ltd.en_US
dc.relation.ispartofInfection and Drug Resistance
dc.subjectAntibioticsen_US
dc.subjectAntimicrobial peptidesen_US
dc.subjectBacterial cell wallen_US
dc.subjectLipid IIen_US
dc.titleTherapeutic compounds targeting Lipid II for antibacterial purposesen_US
dc.typeArticleen_US
dc.identifier.doi10.2147/IDR.S215070


This item appears in the following Collection(s)

Show simple item record